IBV QX疫苗标记的鉴定:权威机构对活IBV疫苗的批准是否应要求类似鉴定?
对IBV QX型活疫苗L1148及其亲本野毒株1148-A进行全共识序列比较,发现28个单核苷酸替换与1148-A致弱相关,其中16个导致氨基酸编码改变、一半位于刺突基因;1b基因一个改变影响S基因转录调控序列末端5个核苷酸。目前尚无突变可关联致弱过程。作者建议注册成功后、疫苗释放前强制向监管机构提交此类比较序列数据。
要点
- L1148与其亲本野毒株1148-A比较发现28个单核苷酸替换与致弱相关。
- 16个替换导致氨基酸改变,其中一半位于刺突基因。
- 1b基因一个改变影响S基因转录调控序列末端高度保守的5个核苷酸。
核心结论
- 28个单核苷酸替换与1148-A致弱相关,任意组合可用于野外识别疫苗L1148。
- 目前尚无突变可关联致弱过程。
- 作者认为注册成功后、疫苗释放前强制向监管机构提交比较序列数据将使野外疫苗接种策略大为受益。
研究设计与样本
- 对活疫苗L1148及其亲本野毒株1148-A进行全共识序列测定与比较。
主要发现
- 28个单核苷酸替换与1148-A致弱相关,任意组合可识别野外疫苗L1148。
- 16个替换导致氨基酸编码改变,其中一半位于刺突基因。
- 1b基因一个改变使S基因转录调控序列末端通常高度保守的5个核苷酸发生改变,该序列为所有IBV QX基因所共有。
临床怎么用
- 作者建议注册成功后、疫苗释放前强制向监管机构提交此类比较序列数据。
局限性
- 目前尚无突变可关联致弱过程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IBV genotype QX causes sufficient disease in Europe for several commercial companies to have started developing live attenuated vaccines. Here, one of those vaccines (L1148) was fully consensus sequenced alongside its progenitor field strain (1148-A) to determine vaccine markers, thereby enabling detection on farms. Twenty-eight single nucleotide substitutions were associated with the 1148-A attenuation, of which any combination can identify vaccine L1148 in the field. Sixteen substitutions resulted in amino acid coding changes of which half were in spike. One change in the 1b gene altered the normally highly conserved final 5 nucleotides of the transcription regulatory sequence of the S gene, common to all IBV QX genes. No mutations can currently be associated with the attenuation process. Field vaccination strategies would greatly benefit by such comparative sequence data being mandatorily submitted to regulators prior to vaccine release following a successful registration process.
引用
- Listorti V, Laconi A, Catelli E, et al. Identification of IBV QX vaccine markers : Should vaccine acceptance by authorities require similar identifications for all live IBV vaccines? Vaccine. 2017. PMID: 28917538. doi:10.1016/j.vaccine.2017.06.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。